Relatively high immunogenicity was reported for reference omalizumab in this study compared with that in previous studies in patients with allergic disease,3, 26 possibly due to the use of a more sensitive and drug‐tolerant ADA assay technology. The gene discussed is ADA; the disease is allergic disease.